• Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network.

AIMS: The clinical effectiveness of buprenorphine-naloxone (bup-nx) and clonidine for opioid detoxification in in-patient and out-patient community treatment programs was investigated in the first studies of the National Institute of Drug Abuse Clinical Trials Network. DESIGN: Diagnostic and Statistical Manual version IV (DSM IV)-diagnosed opioid-dependent individuals seeking short-term treatment were randomly assigned, in a 2 : 1 ratio favoring bup-nx, to a 13-day detoxification using bup-nx or clonidine. METHODS: A total of 113 in-patients (77 bup-nx, 36 clonidine) and 231 out-patients (157 bup-nx, 74 clonidine) participated. Supportive interventions included appropriate ancillary medications and standard counseling procedures guided by a self-help handbook. The criterion for treatment success was defined as the proportion of participants in each condition who were both retained in the study for the entire duration and provided an opioid-free urine sample on the last day of clinic attendance. Secondary outcome measures included use of ancillary medications, number of side effects reported and withdrawal and craving ratings. FINDINGS: A total of 59 of the 77 (77%) in-patients assigned to the bup-nx condition achieved the treatment success criterion compared to eight of the 36 (22%) assigned to clonidine, whereas 46 of the 157 (29%) out-patients assigned to the bup-nx condition achieved the treatment success criterion, compared to four of the 74 (5%) assigned to clonidine. CONCLUSION: The benefits of bup-nx for opioid detoxification are supported and illustrate important ways in which clinical research can be conducted in community treatment programs.

Pubmed ID: 16042639

Authors

  • Ling W
  • Amass L
  • Shoptaw S
  • Annon JJ
  • Hillhouse M
  • Babcock D
  • Brigham G
  • Harrer J
  • Reid M
  • Muir J
  • Buchan B
  • Orr D
  • Woody G
  • Krejci J
  • Ziedonis D
  • Buprenorphine Study Protocol Group

Journal

Addiction (Abingdon, England)

Publication Data

August 26, 2005

Associated Grants

  • Agency: NIDA NIH HHS, Id: U10 DA013045
  • Agency: NIDA NIH HHS, Id: U10 DA013720
  • Agency: NIDA NIH HHS, Id: U10 DA13035
  • Agency: NIDA NIH HHS, Id: U10 DA13036
  • Agency: NIDA NIH HHS, Id: U10 DA13043
  • Agency: NIDA NIH HHS, Id: U10 DA13045
  • Agency: NIDA NIH HHS, Id: U10 DA13046
  • Agency: NIDA NIH HHS, Id: U10 DA13710
  • Agency: NIDA NIH HHS, Id: U10 DA13720
  • Agency: NIDA NIH HHS, Id: U10 DA13732

Mesh Terms

  • Adult
  • Buprenorphine
  • Clonidine
  • Female
  • Humans
  • Inactivation, Metabolic
  • Male
  • Naloxone
  • Narcotic Antagonists
  • Opioid-Related Disorders